EARLY ACHIEVEMENT OF MINIMAL DISEASE ACTIVITY IN PSORIATIC ARTHRITIS IS ASSOCIATED WITH LONG-TERM IMPROVEMENTS IN QUALITY OF LIFE
Authors: Snoeck Henkemans S et al.
MDA is a treatment target in PsA that includes skin, joints, enthesitis as well as the patient’s perspective. The present study was set up to compare the quality of life after 1, 2 and 3 years in PsA patients from the Dutch Southwest Early PsA Cohort (DEPAR) who achieve MDA within the first year or not. Patients were categorized into the following groups: sustained MDA (MDA at both 9 and 12 months visit), non-sustained MDA (MDA achieved within the first year but subsequently lost at 9 or 12 months) and non-MDA (patients who did not achieve MDA during the first year). The SF36 was used after 1, 2 and three years. From 243 patients, 113 achieved sustained MDA, 64 non-sustained MDA and 66 did not achieve MDA. Median symptom duration at baseline was 9.3 months. Quality of life (QoL) in the group of patients with sustained MDA was comparable to the general Dutch population. Patients who did not achieve MDA in the first year had a lower QoL compared to patients in sustained MDA and these differences persisted during the following years despite more intensified treatments.
Aiming for MDA already during the first year after PsA diagnosis may seem very ambitious-but this data shows impressively how the achievement of sustained remission during the first year is associated with better quality of life during the following years and is not compensated by a more intensified treatment later on.